200 related articles for article (PubMed ID: 24511019)
1. Health utilities in gynecological oncology and mastology in Germany.
Hildebrandt T; Thiel FC; Fasching PA; Graf C; Bani MR; Loehberg CR; Schrauder MG; Jud SM; Hack CC; Beckmann MW; Lux MP
Anticancer Res; 2014 Feb; 34(2):829-35. PubMed ID: 24511019
[TBL] [Abstract][Full Text] [Related]
2. Preferences for health outcomes and cost-utility analysis.
Torrance GW
Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
[TBL] [Abstract][Full Text] [Related]
3. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in patients with melanoma expressed as utilities and disability weights.
Tromme I; Devleesschauwer B; Beutels P; Richez P; Leroy A; Baurain JF; Cornelis F; Bertrand C; Legrand N; Degueldre J; Thomas L; Legrand C; Lambert J; Haagsma J; Speybroeck N
Br J Dermatol; 2014 Dec; 171(6):1443-50. PubMed ID: 25039853
[TBL] [Abstract][Full Text] [Related]
6. [Study on medical economic evaluation methods for metastatic brain tumors therapy].
Takura T; Hayashi M; Muragaki Y; Iseki H; Uetsuka Y
No Shinkei Geka; 2010 Jul; 38(7):629-37. PubMed ID: 20628189
[TBL] [Abstract][Full Text] [Related]
7. Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?
Matter-Walstra K; Klingbiel D; Szucs T; Pestalozzi BC; Schwenkglenks M
Pharmacoeconomics; 2014 Jun; 32(6):591-9. PubMed ID: 24671924
[TBL] [Abstract][Full Text] [Related]
8. QALY weights for diabetic retinopathy--a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO.
Heintz E; Wiréhn AB; Peebo BB; Rosenqvist U; Levin LÅ
Value Health; 2012 May; 15(3):475-84. PubMed ID: 22583458
[TBL] [Abstract][Full Text] [Related]
9. [Valuation of health-related quality of life and utilities in health economics].
Greiner W; Klose K
Z Evid Fortbild Qual Gesundhwes; 2014; 108(2-3):120-5. PubMed ID: 24780709
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the relationship between body mass index and EQ-5D health utilities in individuals with type 2 diabetes: evidence from the population-based KORA studies.
Hunger M; Schunk M; Meisinger C; Peters A; Holle R
J Diabetes Complications; 2012; 26(5):413-8. PubMed ID: 22699110
[TBL] [Abstract][Full Text] [Related]
11. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
12. [Health Status of the German population: results of a representative survey using the EuroQol questionnaire].
König HH; Bernert S; Angermeyer MC
Gesundheitswesen; 2005 Mar; 67(3):173-82. PubMed ID: 15789280
[TBL] [Abstract][Full Text] [Related]
13. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
Lillegraven S; Kristiansen IS; Kvien TK
Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
[TBL] [Abstract][Full Text] [Related]
14. [Information technology in gynecological oncology today].
Kupka MS; Richter O; Tutschek B
Zentralbl Gynakol; 2003 Nov; 125(11):446-51. PubMed ID: 14634873
[TBL] [Abstract][Full Text] [Related]
15. The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations.
Cohn DE; Ko E; Meyer LA; Wright JD; Temkin SM; Foote J; Jones NL; Havrilesky LJ
Gynecol Oncol; 2017 Apr; 145(1):185-191. PubMed ID: 28258763
[No Abstract] [Full Text] [Related]
16. Responsiveness of EQ-5D utility indices in alcohol-dependent patients.
Günther OH; Roick C; Angermeyer MC; König HH
Drug Alcohol Depend; 2008 Jan; 92(1-3):291-5. PubMed ID: 17888587
[TBL] [Abstract][Full Text] [Related]
17. Systematic overview of cost-utility assessments in oncology.
Earle CC; Chapman RH; Baker CS; Bell CM; Stone PW; Sandberg EA; Neumann PJ
J Clin Oncol; 2000 Sep; 18(18):3302-17. PubMed ID: 10986064
[TBL] [Abstract][Full Text] [Related]
18. The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease.
Leidl R; Reitmeir P; König HH; Stark R
Value Health; 2012 Jan; 15(1):151-7. PubMed ID: 22264983
[TBL] [Abstract][Full Text] [Related]
19. Italian population-based values of EQ-5D health states.
Scalone L; Cortesi PA; Ciampichini R; Belisari A; D'Angiolella LS; Cesana G; Mantovani LG
Value Health; 2013; 16(5):814-22. PubMed ID: 23947975
[TBL] [Abstract][Full Text] [Related]
20. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
